Brian Melley
Podiatrist · Florala, ALNPI 1750449526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Organogenesis Inc. at 28.6% of the total. 2025 is the largest year on record at $231, 2.4 times the $98 reported in 2019. That places this record below the midpoint for podiatrist clinicians in AL, where the typical reported total is $1,120.
Across 25 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$183
- Kerecis Limited$153
- Tactile Systems Technology Inc$98
- IBSA Pharma Inc.$44
- Nevro Corp.$43
- Averitas Pharma Inc.$40
- plus $78 from 3 others
What the payments were for
- Food & beverage$640100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 10 | $183 |
| Kerecis Limited | 3 | $153 |
| Tactile Systems Technology Inc | 1 | $98 |
| IBSA Pharma Inc. | 2 | $44 |
| Nevro Corp. | 3 | $43 |
| Averitas Pharma Inc. | 2 | $40 |
| Ossur Americas, Inc. | 1 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Globus Medical | 1 | $16 |
How this compares
$640 in reported general payments places this provider in the 35th percentile of 59 podiatrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 161 | $2,791 |
| Lidocaine | 12 | $961 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $635 |
| Gabapentin | 63 | $597 |
| Ketoconazole | 16 | $185 |
| Cephalexin | 18 | $151 |
| Meloxicam | 20 | $29 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Florala
- Michael HamesFlorence$100K
- James MorganMobile$21K
- John RobersonBirmingham$10K
- Kyle MaukBirmingham$10K
- Johnnie AlstonMontgomery$9K
- Heidi ChristieMontgomery$7K
- Brent HaverstockBirmingham$7K
- David LindeBirmingham$6K
- Robert OcampoCullman$5K
- Jamie ClecklerBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.